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Background.Thestudywas undertaken to elicit the knowledge, views, and perceptions of key stakeholders onmalaria, its bioburden,
and treatment options, in order to ascertain the knowledge gabs and challenges, especially in the use of oral quinine in childhood
malaria.Methods.A cross-sectional surveywas conducted using awell-structured Likert Scale and self-administered questionnaire.
The principal site of the studywas a government-run children’s hospital located in theAshieduKeteke Sub-Metro ofAccra.The study
population included health workers, parents, and guardians or care givers. The participants were 300, purposively selected, and
consisted of both men (41%) and women (59%) who were twenty years and above, whether employed (42%), self-employed (37%),
or unemployed (21%). Results. Majority of the participants (78%) demonstrated above average knowledge of malaria. However,
their awareness of the causes, modes of transmission, signs, and symptoms as well as preventive mechanisms of malaria did not
result in low incidence of malaria. About 77% of the respondents agreed they would seek treatment within 24 hours once signs
and symptoms are detected. Though close to 50% undertook home treatment of malaria, majority eventually sought treatment at
hospital or clinic. Above 92% of respondents knew that quinine is used to treat malaria and agreed its bitter taste greatly affects
compliance, especially in children. Consequently, 95% of the respondents would be glad if its bitter taste is masked. Conclusion.The
study demonstrated the availability of substantial knowledge of the devastating effects of malaria, especially in children.Therefore,
there is the need to ensure the availability and utilization of effective paediatric formulations in the fight against malaria. From this
study, fast dissolving oral thin film with a good mouth feel, would be the formulation of choice for quinine.
1. Introduction
Malaria is a serious and potentially fatal disease caused by the
parasite, Plasmodium. There are four species of this parasite
which cause the disease in humans, namely, P. falciparum,
P. vivax, P. malariae, and P. ovale. These parasites are
transmitted basically through the bites of female Anopheles
mosquitoes [1, 2]. Malaria caused by P. falciparum is the
deadliest form and the most predominant in Africa. The P.
vivax is less dangerous but more widespread [3]. Symptoms
of malaria are generally nonspecific and commonly consist of
fever, malaise, weakness, gastrointestinal complaints (nausea,
vomiting, and diarrhoea), neurological complaints (dizzi-
ness, confusion, and coma), and myalgia [4]. Others include
headache, chills and/or cough, back and joint pains, delirium,
convulsions, and anaemia [5].
Malaria continues to be a major public health concern in
many countries of the world despite the efforts and progress
made in reducing malaria cases and deaths. An estimated
number of 214 million cases of malaria were recorded across
the world in 2015 and this resulted in 438,000malaria deaths,
90% of which occurred in Africa [6]. The disease burden
is highest in poor, rural areas and deprived populations,
contributing annually to an estimated 1.3% reduction in
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economic growth in high-burden countries [7], and reduces
school attendance, impairs cognitive development in chil-
dren, and lowers productivity [8].
Malaria can be effectively prevented and treated using
tools that exist today [9]. A multipronged approach using
insecticide treated nets (ITNs), indoor residual spraying
(IRS), intermittent preventive treatment (IPT) of pregnant
women and children, and prompt diagnosis and treatment
using ACTs and other antimalarial agents such as quinine
has been proven to prevent death and significantly reduce
illness [10]. The way forward then is to improve education
and sensitization of the populace, establishment of effective
collaborations and the provision of the right tools, and
improving access. Being largely a disease of poverty, malaria
and its effects would be greatly reduced by improvement in
the living conditions of the people. Others will include the
adaptation of new approaches to the handling and treatment
of malaria. The engagement and use of community health
officers fromboth healthcare and social services sectors could
help develop malaria plans and policies capable of providing
preventive, promotional, and medical care to individuals and
communities.
With children being the most vulnerable group among
malaria patients, this study sought to identify the challenges
and knowledge gabs associated with these interventions
that would need to be addressed in order to improve and
enhance malaria treatment outcomes, especially with the use
of quinine in children.
2. Materials and Methods
2.1. Study Design. This was a cross-sectional study. The
primary study method was the use of a well- structured ques-
tionnaire. It was carefully designed such that respondents
had options to choose responses ranging from strongly agree,
agree, neutral, and disagree to strongly disagree.
2.2. Study Site. This study was undertaken at a government
children’s hospital chosen because of its role in the healthcare
delivery in the country. The hospital is located within the
Ashiedu Keteke Sub- Metro area of the Greater Accra region.
It is situated very close to the central business district of
Ghana’s capital, Accra, and very close to the popular Makola
market, which facilitates easy access.
2.3. Study Population. Participants in the study were health-
care personnel, parents, guardians, and caregivers.Thesewere
selected as the target population because of their relationship
with the child and their roles in paediatric healthcare delivery.
A total of 748 participants were involved.
2.4. Sampling. Participants were purposively selected and
included bothmen andwomenwhowere at least twenty years
old at the time of sampling.
2.5. Ethical Considerations. Ethical approval for the study
was obtained from the Committee on Human Research,
Publication and Ethics, Kwame Nkrumah University Science
and Technology, and Komfo Anokye Teaching Hospital (Ref:
CHRPE/AP/017/17). Participants in the study were provided
with the participant information leaflet and signed the con-
sent forms prior to their participation. Those who could not
read had it explained to them in their local dialect and their
consent was thereafter given before they participated. The
rationale of the study and all the issues concerning human
ethics were carefully explained in the introduction to the
online forms.
2.6. Data Collection Procedure. Data collection was made
by a well-structured and self-administered questionnaire to
obtain quantitative primary data. The study was conducted
by the use of both hard copy and online questionnaire.
The online questionnaire for quantitative data collection
was via Internet based Google forms for the distribution of
questionnaires and data collection throughparticipant emails
and web link invitations. Reminder emails were sent to the
respondents during the data collection period to enhance
respondent participation. In the case of participants with
poor Internet connectivity and power cuts, respondents were
given hard copies of the questionnaire with explanation of
information contained in the leaflet to obtain due consent
and followed up promptly for the collection of the filled-
in questionnaire. Prior to the administration of the survey
questionnaires, the duration, competency, and suitability of
the questionnaires were pretested and returned a Cronbach’s
alpha reliability statistic of 0.904, an indication that the
questionnaires were competent [11, 12].
The entire questionnaire was composed of two major
parts. Part I took the biodata of the respondents. Part II on
the other hand was subsectioned into various categories and
captured data on the respondents’ knowledge on malaria,
preventive measures and treatment seeking attitude, pae-
diatric drug formulations, antimalarial drug use options,
quinine antimalarial therapy, and novel quinine formulations
for children. The questionnaire (Part II) was designed in
the form of Likert rating scale, from (1) strongly agree, (2)
agree, (3) neutral, and (4) disagree to (5) strongly disagree.
Participants indicated their level of agreement with the
statements in each section by ticking the appropriate op-
tion.
2.7. Statistical Processing of Data. The SPSS version 20 was
used to test for the internal consistency of the question-
naires to solicit the intended responses from the partici-
pants in the pretest. Data from 20 respondents obtained
using Google forms (spreadsheets) were entered into the
SPSS, and the Cronbach’s alpha reliability statistic was deter-
mined.
The online forms were filled and returned, while
responses from the hard copy questionnaires were filled
manually into the Google forms. For the continuous data
processing of the items in Part I, percentages were generated
from the responses in the summary of the Google forms
spreadsheet for the univariate analysis. Quantitative data
for Part II was processed and automatically formatted into
aggregated data charts for univariate analysis.
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Table 1: Sociodemographic distribution of the study participants.
Characteristic Frequency (n) Percentage (%)
Age range in years
20 – 30 267 35.69
31 – 40 256 34.23
41 – 50 123 18.05
51 – 60 64 9.22
61 – 70 17 2.27
70 + 3 0.54
Gender
Male 303 40.51
Female 455 59.49
Marital status
Single 289 38.64
Married 459 61.36
Education level
Primary 74 9.89
Secondary 265 35.43
Tertiary 393 52.54
Other 16 2.14
Employment status
Unemployed 159 21.26
Self-employed 279 37.30
Employed 310 41.44
Role in care giving
Healthcare professional 199 26.60
Parent/guardian/caregiver 549 73.40
3. Results and Discussion
3.1. Biodata Distribution of the Study Participants. A total
of 748 successfully completed questionnaires were obtained
and comprised of 59% female and 41% male respondents.
Majority of the respondents (53%) had attained tertiary edu-
cation and 35% had secondary education, with the other 12%
having left school at the primary level or other forms of basic
education. Majority of the respondents (73%) were parents,
guardians, or caregivers, while the other 27% were clinicians,
nurses, and pharmacists. About 21% of the respondents were
unemployed, but a greater proportion (79%) were either
employed or self-employed (Table 1).
3.2. Causes and Modes of Malaria Transmission. The study
revealed that most of the respondents had a high level of
understanding of the causes of malaria and its mode of
transmission. Majority of the respondents associated malaria
with the Plasmodium parasite (68%) and its spread through
the bites of the infected female Anopheles mosquitoes (75%)
(Figure 1). The extent of knowledge of the true causes of
malaria from this study is similar to some earlier findings
in Nigeria [13], Zimbabwe [14], Cameroon [15], and India
[16], which all indicated an improvement over some related
studies previously undertaken in Ghana and elsewhere. In
those earlier findings, malaria was largely associated with
some misconceptions such as drinking of dirty water, eating
of oily foods, standing in the sun among others [17, 18].
Generally, the participants agreed that malaria cases
become more widespread during the rainy season (75%)
and identified children and pregnant women as the most
vulnerable population (65%) formalarial attacks. Fortunately,
the respondents (82%) indicated that malaria is not an evil
disease as they dispelled the influence of witchcraft as a
cause of malaria. The high knowledge level observed can be
attributed to the educational levels of the participants in this
study as some other findings also related education to one’s
awareness of malaria [19, 20].
Essentially, knowledge of the real causes and modes of
transmission of malaria would be beneficial in the quest for
malaria prevention.
3.3. Awareness of the Signs and Symptoms of Malaria. Major-
ity of the respondents rightfully identified the signs and
symptoms of malaria to include fever (75%), headache and
dizziness (74%), general weakness (73%), nausea and vomit-
ing (62%), loss of appetite (68%), and the resultant anaemia
(63%) (Figure 2). These findings are similar to reports from
some related works undertaken earlier on the subject [21,
22]. Knowledge of the right signs and symptoms would
principally influence an individual’s ability to take prompt
and proper action at the onset of malaria, thereby triggering
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Figure 1: Awareness of the causes of malaria.
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Figure 2: Knowledge of the signs and symptoms of malaria.
an appreciable treatment seeking attitude. TheWHO and UK
malaria treatment guidelines recommend early diagnosis and
treatment as very essential in fighting malaria [23, 24].
Substantial understanding of the signs and symptoms of
malaria can be crucial for homemanagement of malaria and,
hence, reduce severity and mortality. Therefore, even though
there was considerable level of awareness of the clinical signs
and symptoms of malaria, health authorities would need
to intensify educational programmes among the populace
aimed at maximum or near maximum malaria management
and control.
3.4. Knowledge of theMethods ofMalariaPrevention. Malaria
is deadly, yet it is an entirely preventable and treatable
disease [2]. Methodologies range from the interference of
breeding grounds and larva control to putting into practice of
Journal of Pharmaceutics 5
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Figure 3: Awareness of the methods of prevention of malaria.
personal and household protective measures [25]. Generally,
the knowledge about malaria prevention methods was high
among the participants (Figure 3). While 97% agreed on
the use of ITNs, 92% indicated IRS as means of preventing
malaria. ITNs and IRS as well as environmental cleanliness
have been used as malaria control mechanisms over the years
[15].
Our study has also identified the use of mosquito
repellents and netted windows and doors, while the wear-
ing of protective clothes against mosquito bites was also
emphasised, similar to several other study findings [26, 27].
Refreshingly, these measures are relatively cheaper than the
use of IRS and ITNs [28] and can be implemented at ordinary
household levels. The results established clearly that there
is a relationship between the knowledge of the causes of
malaria and its prevention. It also seems clear that the
education and interventions by the National Malaria Control
Programme is yielding the desired impact, and if intensified,
the anticipated malaria cases will subside [27]. Therefore,
children under 5 years and pregnant women in malaria
endemic communities should continue to be targets in the
malaria control programmes such as free or subsidized ITNs
distribution and effective treatment via maternal and child
health clinics.
3.5. Malaria Disease Management. The incidence of malaria
was high in the study population, especially childhood
malaria as 84% of respondents had children who had expe-
rienced malaria in the past. Further, 93% agreed that malaria
is a serious and life-threatening disease which can kill if
not treated promptly. The high level of knowledge of the
deadly nature of malaria is encouraging, because proper
measures would be taken to prevent ormanage it should their
family members get infected. Unfortunately, however, despite
the fact that majority of the respondents had high level of
knowledge on aptmalaria preventionmethods, their children
(84%) still had episodes of malaria infection at one point or
the other.
It therefore appears that the challenges tomalaria preven-
tion are still enormous and complicated. Lack of adequate
protective clothing, the hot and humid Tropical African
weather which does not support or encourage thorough body
covering and use of ITNs, abundance of the mosquito vector
in the subregion coupled with changes in their feeding times
and habits, lack of effective IRSs, or the mere inability to
implement the knowledge onmalaria prevention exacerbates
these challenges. Mboera et al. [29], in a similar study
observed that in spite of high levels of knowledge of malaria
in Tanzania, its morbidity was still high, and they suggested
that misguided application of antimalarial drugs and delayed
health seeking attitude as well as reliance on clinical findings
in the absence of laboratory confirmation were accounta-
ble.
Treatment seeking attitude was good although pockets
of participants agreed on undertaking home treatment with
either previously bought drugs or herbal products. Essen-
tially, majority of the respondents sought formal healthcare
services from hospitals, clinics, or the community health
workers [30], although some other studies [31] contradict this
in favour of home treatment of some kind.
Interestingly, the study showed that 77% of the partici-
pants would seek treatment within 24 hours once symptoms
showed up, which is in line with the targets of the Abuja
Summit onMalaria which among other things envisaged that
at least 60% of those having malaria should seek treatment
within 24 hours of the onset of symptoms [32].
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Nevertheless, some of the participants identified long dis-
tances to health facilities, high transportation, consultation
and treatment costs, unfriendly attitude of some healthcare
workers, unnecessary delays at the health facilities, and busy
work schedules as some of the reasons for not seeking formal
healthcare (Table 2).
Some form of continuing health education is still neces-
sary to help these parents understand the need to take their
children to healthcare centres for treatment in spite of these
difficulties and challenges. Maybe the introduction of some
basic incentives for prompt healthcare seeking attitudes,
especially with children and pregnant women, could greatly
enhance this. Also, since malaria is still a major killer in
Africa, there is the need to restructure the health systems
to facilitate the use of community health officers (CHOs) to
take malaria control to the populace rather than wait and
expect them to use the health facilities, in view of the high
level of poverty and low literacy in these communities. The
use of CHO services has been widely demonstrated to be
very effective and have resulted in the elimination of most
childhood killer diseases in many communities, improving
family planning services and lifestyles of, especially, mothers
and children [33].
Meanwhile some health workers in the various centres
would need a rethink in attitude towards patients and
guardians who seek healthcare services from them. This
may require further training and continuous professional
development, where some of these findings are conveyed to
these practitioners.
3.6. Desirable Attributes of Paediatric Drug Formulations.
The use of off-label and unlicensed medicines in children is
widespread, yet the effects of these medicines on children
have not been properly studied. Healthcare professionals,
parents, or caregivers are often confronted with the necessity
to manipulate an adult medicine for children which has the
potential for high levels of dosage errors, instability, poor
bioavailability, and unintended side-effects. Children under
five years have been the target for antimalarial drug therapies
over the years. The availability and suitability of antimalarial
drug formulations for the child are essential if the fight against
paediatric malaria is to be won.
Suitable formulations for children make it easier for
parents and caregivers to administer antimalarial agents
effectively, resulting in better therapeutic outcomes [34, 35].
Paediatric formulation ought to satisfy the needs: convenient
and reliable administration, acceptability and palatability,
minimum dosing frequency, end-user needs of patients
of diverse ages, and the preferences of patients including
caregivers in different parts of the world [36, 37].
Age-appropriate dosage forms are necessary to ensure
compliance and effective therapeutic outcomes [38]. Liquid
formulations hitherto had been the formulation of choice for
paediatric use but issues of compliance and safety have been
expressed. Liquid formulations can easily undergo microbial
contamination if proper storage conditions are not followed.
Most antimalarial agents also have unpleasant taste and bitter
tasting drugs are usually poorly tolerated by children. A
significant proportion (85%) of the study participants were
aware of some paediatric antimalarial drug formulations in
circulation and showed preference for formulations which
are palatable, easily acceptable, and in an attractive packaging
(Figure 4).
Palatability and dysphagia persist as the two paramount
challenges to paediatric drug product development, because
neither is trivial and therefore continues to bemajor obstacles
to the development of ‘child-friendly’ dosage forms [39].
3.7. Antimalarial Drug Knowledge. The study uncovered that
some antimalarial drugs were more common among the
participants than others (Table 3). Quinine came topmost
(92%) followed by chloroquine (90%) as the antimalarial
agents most of the respondents were familiar with. This may
be because of the unique bitter taste of the duo as many
people are more likely to remember bad taste.The availability
of quinine tonic on the market may have an influence. In
addition, quinine has been in use for treating malaria for
over two centuries now and so the awareness of it among the
respondents is fairly understandable. Unfortunately, chloro-
quine, though well known, has fallen into disuse and is no
longer recommended due to drug resistance resulting from
dosing errors, inappropriate use, or misuse and abuse.
The knowledge of the respondents on the ACTs was
appreciable, but artesunate-amodiaquine (92%) and arte-
mether-lumefantrine (87%) were the most common among
the respondents (Table 3). Lonart (92%), Coartem (87%),
Lumether (78%), and Malar-2 (67%) were, respectively, the
leadingmarketed brands of ACTs, in respect of the knowledge
of the respondents. The Governments’ recent policy on the
use of ACTs and the education and advertising that have gone
on with it could have played a major role in this outcome.
The challenges here are the lack of proper understanding
of the term ACT and the proliferation of numerous brands
with varying efficacy and effectiveness. In addition, treatment
failures with these unreliable brands have emphasised the use
of quinine.
3.8. Knowledge of Quinine AntimalarialTherapy. Quinine has
been an age-old drug used for the treatment of malaria.
Although, the WHO does not recommend it as a first line
antimalarial drug for uncomplicated malaria, quinine is still
used in the treatment of severe malaria and in cases where
the ACTs fail to give the required therapeutic outcome. It was
known among majority of the study participants that quinine
is used for treating both complicated and uncomplicated
malaria (Table 4), as supported by the UK malaria treatment
guidelines [23].
Quinine, a cinchona alkaloid, has been an important
antimalarial agent for a long time and continues to be
effective against chloroquine-resistant P. falciparum malaria
[40]. In settings where multidrug resistant strains prevail, a
7-day regimen of quinine plus tetracycline or doxycycline or
clindamycin gives cure rates of over 90% for patients with P.
falciparummalaria [41]. Quinine use in children is chiefly in
the form of syrups which are sweetened because of its bitter
taste. There are no other paediatric formulations of quinine,
and when treating children, care should be taken to ensure
Journal of Pharmaceutics 7
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Figure 4: Desirable attributes of paediatric drug formulations.
correct doses are administered and retained because of its
bitter taste and the fear of vomiting.
The unpalatability of quinine syrups as well as the
crushed tablets may lead to the use of subtherapeutic dosages,
noncompliance, and potential development of parasitic resis-
tance. The study has revealed that the participants were
familiar with the difficulties regarding quinine use in chil-
dren, such as the bitter taste, and agreed that the bitterness
of quinine is affecting their children’s acceptance of the
drug. As such the oral administration of large of volumes
of quinine syrup may be difficult to achieve in children.
Hence, 89% of the respondents agreed that they would be
happy if the bitterness of quinine can be masked. This poses
a challenge and places a burden of trust and responsibility on
academia and industry players to act decisively and quickly.
The WHO initiative “Make Medicine Child Size”, aimed at
increasing awareness and access to child specific medicines
[42], and the European Paediatric Formulation initiative [43]
both seek to promote the preparation of effective and safe
children medications by facilitating the sharing of expertise
between key stakeholders in the health industry. These are
aimed at identifying and dealing with common challenges in
developing formulations for paediatric populations. Ideally,
formulations meant for children should possess minimal
frequency of dosing, insignificant impact on lifestyle, min-
imum safe excipients, and wide range of applicability and
should as well be easy to produce, stable, elegant, cost-
effective, and commercially available [44, 45].
3.9. Choice of Novel Oral Paediatric Quinine Formulations. As
a solution to some of the challenges enumerated with respect
to quinine use in children, the study sought to determine
the formulation of choice of quinine for paediatric use. It
became clear that majority of the participants (91%) generally
favoured oral thin film/strip formulation and some92%of the
respondents agreed that they would appreciate a formulation
that guarantees a good mouth feel (Figure 5).
Fast dissolving oral thin films have become the cutting-
edge form of oral solid dosage forms in view of more
flexibility and comfort [46].They are more easily tolerated by
patients and caregivers with respect to their ease-of-delivery,
accurate dosing, and portability [47–49]. It enhances the
dissolution and efficacy of drugs in a matter of seconds in the
oral cavity once it gets into contact with saliva and therefore
requires no water or mastication for administration [50, 51].
The predetermined form of oral dissolving thin films
(ODTFs) offers an accurate and easily swallowed dose with-
out water that allows for portable and convenient “give
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Table 3: Knowledge on the availability of some antimalarial drugs.
Antimalarial drug Strongly agree (%) Agree (%) Neutral (%) Disagree (%) Strongly disagree (%)
Chloroquine 57.5 32.8 5.5 1.5 2.8
Quinine 66 25.8 5.2 1.3 1.6
Amodiaquine 59.6 30.5 6.3 1.7 1.9
Halofantrine 17 16.7 41.6 13.8 11
Primaquine 12.7 16.3 44.1 14.6 12.3
Mefloquine 11.6 17.6 43.9 2.7 12.4
Artesunate 57.1 22.5 12.6 3.1 4.8
Dihydroartemisinin 18.9 23.8 34.4 13.2 9.8
Piperaquine 12.4 24.6 36.8 14.3 11.9
Sulfadoxine & Pyrimethamine 19.5 20.9 34.6 12.7 12.3
ACTs
Artesunate + amodiaquine 69.5 22.5 4.3 1.3 2.4
Artemether + lumefantrine 61 25.5 8.2 2.4 2.9
Dihydroartemisinin + piperaquine 21.1 25.3 33.2 11.9 8.6
Artesunate + Mefloquine 10.8 21.4 40.1 16.8 10.8
Artesunate + Sulfadoxine & Pyrimethamine 12.2 22.2 39.3 15.6 10.8
Marketed Brands of ACTs
Lonart 63.8 28.5 4.5 1.1 2.1
Coartem 57.8 29.4 7 2.5 3.3
Lumether 50.9 27.5 14.3 3.3 3.9
Malar- 43.3 23.7 19.7 7 6.4
P-Alaxin 35.3 24.9 24.5 8 7.4
Danmether 31 20.5 31 9 8.6
Gen-M 34.5 15.6 25.4 9.8 14.7
Table 4: Knowledge on quinine antimalarial therapy.
Knowledge on quinine antimalarial
therapy
Strongly
agree (%) Agree (%) Neutral (%) Disagree (%)
Strongly
disagree (%)
I’ve given quinine to a child for malaria
before 38.4 27.3 16 7.4 11
Quinine treats both complicated and
uncomplicated malaria 35.4 41.4 14.2 3.3 5.6
Quinine has a bitter taste 70.5 17.9 7.4 1.6 2.7
Quinine’s bitterness is affecting my child’s
acceptance 59.1 25.7 10.6 1.2 3.5
I will be happy if the bitterness can be
masked 71.9 16.6 7.1 1.6 2.8
Tinnitus, headache, nausea, etc. appear
after taking quinine 23.3 26.2 37 4.9 8.6
Oral administration of large volumes of
quinine syrup may be difficult to achieve 58.8 24.7 10.3 2.5 3.6
and go” administration by a caregiver or parent [52]. It
facilitates quick absorption and instant bioavailability of
drugs due to high blood flow and permeability within the oral
cavity.
Fast dissolving thin films are particularly useful in
patients of such groups as paediatric, geriatric, emetic, and
the bedridden [53, 54]. Oral thin films have the fundamen-
tal benefit of accuracy of dosing as compared to liquids,
and there is no fear of choking as in the case of tablets
and capsules. The novelty of the oral thin film is that
it dissolves rapidly in the mouth invariably within 10–15
seconds [55].
Therefore, quinine inODTFswith a good ‘mouth feel’ will
provide the key to an efficient and effective use of quinine in
childhood malaria.
4. Conclusion
The study demonstrated the availability of substantial knowl-
edge of various aspects of malaria as well as its devastating
10 Journal of Pharmaceutics
76
.7
26
.9
20
.7 23
80
.4
14
.4
33
24
.3 29
.9
11
.6
6.
7
28
.9
37
.3
30
6.
1
0.
7 4.
6 9
.1 8.
4
0.
91.
4 6
.7 8.
6
8.
7
1
0
10
20
30
40
50
60
70
80
90
100
Fast dissolving strips Orodispersible tablets Xerogels Chewable tablets for
older children
good mouth feel
Strongly disagree Agree Neutral Disagree Strongly disagree
Figure 5: Novel paediatric quinine formulations.
burden, especially in children. Yet, the significant knowledge
did not yield much in reduction of malaria episodes. The
study has thus emphasised the need to ensure that tools
such as insecticides treated nets and efficacious antimalarial
agents are made available and utilised effectively in the fight
against malaria. The availability of appropriate formulations
of paediatric antimalarial agents such as quinine and its right
usage would be key in any future malaria control strategies.
The formulation of choice for quinine in the light of this study
is the fast dissolving oral thin film which comes along with it
efficient taste masking opportunities as well as guaranteeing
a good mouth feel. Additionally, to control malaria some
level of education is needed. Populations that demonstrate
incorrect knowledge of malaria and its therapy may be
illiterate or possess a low level of formal education. Therefore,
there is a need for continued education since malaria control
has somany facets and education is key to its success. Malaria
control should be handled in a systematic, multisectoral, and
coordinated manner to be effective.
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